{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:07:18Z","timestamp":1792793238280,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00277-022-05058-5","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:15:44Z","timestamp":1670062544000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The emerging therapeutic landscape of relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"102","author":[{"given":"Benjamin","family":"Tanenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Miett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"5058_CR1","unstructured":"National Cancer Institute. Cancer Stat Facts: Myeloma. 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 10 Nov 2022"},{"key":"5058_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327:464\u2013477","journal-title":"JAMA"},{"key":"5058_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705\u2013716","journal-title":"N Engl J Med"},{"key":"5058_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398:314\u2013324","journal-title":"Lancet"},{"key":"5058_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726\u20131737","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"5058_CR6","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","volume":"39","author":"JLD Anderson","year":"2021","unstructured":"Anderson JLD, Munshi NC, Shah N et al (2021) Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. J Clin Oncol 39(15_suppl):8016\u20138016","journal-title":"J Clin Oncol"},{"key":"5058_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2021-146060","volume":"704","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani S, Berdeja J et al (2021) Updated results from CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed chimeric antigen receptor t cell therapy, in patients with relapsed\/refractory multiple myeloma. Blood 704:549","journal-title":"Blood"},{"key":"5058_CR8","doi-asserted-by":"publisher","unstructured":"Martin T, Usmani SZ, Berdeja JG et al (2022) Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol.\u00a0https:\/\/doi.org\/10.1200\/JCO.22.00842","DOI":"10.1200\/JCO.22.00842"},{"issue":"16_suppl","key":"5058_CR9","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1200\/JCO.2022.40.16_suppl.8028","volume":"40","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Martin TG, Berdeja JG et al (2022) Phase 1b\/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed\/refractory multiple myeloma (CARTITUDE-1): two years post-LPI. J Clin Oncol 40(16_suppl):8028\u20138028","journal-title":"J Clin Oncol"},{"key":"5058_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG et al (2018) CD38 antibodies in multiple myeloma: back to the future. Blood 131:13\u201329","journal-title":"Blood"},{"key":"5058_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M et al (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7:311\u2013320","journal-title":"MAbs"},{"key":"5058_CR12","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840\u20131848","journal-title":"J Immunol"},{"key":"5058_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754\u2013766","journal-title":"N Engl J Med"},{"key":"5058_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331","journal-title":"N Engl J Med"},{"key":"5058_CR15","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV et al (2019) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394:2096\u20132107","journal-title":"Lancet"},{"key":"5058_CR16","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397:2361\u20132371","journal-title":"Lancet"},{"key":"5058_CR17","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai YT, Acharya C, An Z et al (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127:3225\u20133236","journal-title":"Blood"},{"key":"5058_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N et al (2021) Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398:665\u2013674","journal-title":"Lancet"},{"key":"5058_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21:207\u2013221","journal-title":"Lancet Oncol"},{"key":"5058_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/01.HS9.0000829628.48136.02","volume":"6","author":"S Usmani","year":"2022","unstructured":"Usmani S, Alonso A, Quach H et al (2022) P14: DREAMM-9: phase I study of belantamab mafadotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. HemaSphere 6:19\u201319","journal-title":"HemaSphere"},{"key":"5058_CR21","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2021-153315","volume":"1","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Alonso AA, Quach H et al (2021) DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. Blood Suppl 1:2738","journal-title":"Blood Suppl"},{"key":"5058_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505","journal-title":"N Engl J Med"},{"key":"5058_CR23","doi-asserted-by":"publisher","unstructured":"Martiniani R, Di Loreto V, Di Sano C et al (2012) Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol 842945. https:\/\/doi.org\/10.1155\/2012\/842945","DOI":"10.1155\/2012\/842945"},{"key":"5058_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.beha.2007.09.002","volume":"20","author":"SK Thomas","year":"2007","unstructured":"Thomas SK, Richards TA, Weber DM (2007) Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 20:717\u2013735","journal-title":"Best Pract Res Clin Haematol"},{"key":"5058_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A et al (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343:301\u2013305","journal-title":"Science"},{"key":"5058_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M et al (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20:781\u2013794","journal-title":"Lancet Oncol"},{"key":"5058_CR27","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW et al (2017) Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 130:974\u2013981","journal-title":"Blood"},{"key":"5058_CR28","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3324\/haematol.2022.280857","volume":"107","author":"M Engelhardt","year":"2020","unstructured":"Engelhardt M, Waldschmidt JM, W\u00e4sch R (2020) Proteasome inhibition: the dawn of novel therapies in multiple myeloma. Haematologica 107:1018\u20131019","journal-title":"Haematologica"},{"key":"5058_CR29","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"5058_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17:27\u201338","journal-title":"Lancet Oncol"},{"key":"5058_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142\u2013152","journal-title":"N Engl J Med"},{"key":"5058_CR32","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","volume":"102","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, Masszi T, Grzasko N et al (2017) Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1. Haematologica 102:1767\u20131775","journal-title":"Haematologica"},{"key":"5058_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","volume":"9","author":"Y Wang","year":"2016","unstructured":"Wang Y, Sanchez L, Siegel DS et al (2016) Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol 9:55","journal-title":"J Hematol Oncol"},{"key":"5058_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W et al (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329\u20131337","journal-title":"Blood"},{"key":"5058_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) ELOQUENT-2 investigators. elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u201331","journal-title":"N Engl J Med"},{"key":"5058_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D et al (2020) (2020) Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10:1\u201310","journal-title":"Blood Cancer J"},{"key":"5058_CR37","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S et al (2018) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379:1811\u20131822","journal-title":"N Engl J Med"},{"key":"5058_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian NG, Li Y (2020) XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol 13:1\u20139","journal-title":"J Hematol Oncol"},{"key":"5058_CR39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","volume":"36","author":"DT Vogl","year":"2018","unstructured":"Vogl DT, Dingli D, Cornell RF et al (2018) Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 36:859\u2013866","journal-title":"J Clin Oncol"},{"key":"5058_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381:727\u2013738","journal-title":"N Engl J Med"},{"key":"5058_CR41","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I et al (2020) Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. The Lancet 396:1563\u20131573","journal-title":"The Lancet"},{"key":"5058_CR42","doi-asserted-by":"crossref","unstructured":"White D, LeBlanc R, Venner C et al (2019) Safety and efficacy of the combination of selinexor, lenalidomide and dexamethasone (SRd) in patients with relapsed\/refractory multiple myeloma (RRMM). 17th International Myeloma Workshop 2019; Abstract 353","DOI":"10.1016\/j.clml.2019.09.084"},{"key":"5058_CR43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519\u2013527","journal-title":"Lancet"},{"key":"5058_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387:132\u2013147","journal-title":"N Engl J Med"},{"key":"5058_CR45","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG et al (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431\u2013e442","journal-title":"Lancet Haematol"},{"key":"5058_CR46","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T et al (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104\u20132115","journal-title":"N Engl J Med"},{"key":"5058_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/blood.2021010744","volume":"138","author":"M Roussel","year":"2021","unstructured":"Roussel M, Lauwers-Cances V, Wuilleme S et al (2021) Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood 138:113\u2013121","journal-title":"Blood"},{"key":"5058_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J et al (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132\u2013141","journal-title":"Lancet"},{"key":"5058_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2021-150519","volume":"653","author":"M Sebag","year":"2021","unstructured":"Sebag M, Raje NS, Bahlis NJ et al (2021) Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood 653:895","journal-title":"Blood"},{"key":"5058_CR50","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Arnulf B, Niesvizky R (2022) Initial safety results for MagnetisMM-3: a phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed\/refractory (R\/R) multiple myeloma (MM). J Clin Oncol 40(16):8006\u20138006","DOI":"10.1200\/JCO.2022.40.16_suppl.8006"},{"key":"5058_CR51","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, Kang J, Amatangelo M et al (2020) Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 34:1197\u20131201","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"5058_CR52","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood-2021-147812","volume":"138","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Ocio E, Raje NS et al (2021) CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): preliminary results from the phase 1\/2 study CC-92480-MM-002. Blood 138(Supplement 1):2731","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05058-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05058-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05058-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T03:49:31Z","timestamp":1672976971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05058-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5058"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05058-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"SAP served on the Multiple Myeloma Advisory Board for Pfizer and serves on the Acute Myeloid Leukemia Advisory Board for Bristol Myers Squibb. SAP has been a consultant for the Dedham Group, SIS International Research, and Adivo Associates.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}